U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C21H28N2O5
Molecular Weight 388.4574
Optical Activity UNSPECIFIED
Defined Stereocenters 5 / 5
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of RAMIPRILAT

SMILES

C[C@H](N[C@@H](CCC1=CC=CC=C1)C(O)=O)C(=O)N2[C@H]3CCC[C@H]3C[C@H]2C(O)=O

InChI

InChIKey=KEDYTOTWMPBSLG-HILJTLORSA-N
InChI=1S/C21H28N2O5/c1-13(22-16(20(25)26)11-10-14-6-3-2-4-7-14)19(24)23-17-9-5-8-15(17)12-18(23)21(27)28/h2-4,6-7,13,15-18,22H,5,8-12H2,1H3,(H,25,26)(H,27,28)/t13-,15-,16-,17-,18-/m0/s1

HIDE SMILES / InChI
Molecular Formula C21H28N2O5
Molecular Weight 388.4574
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 5 / 5
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/16398929

Ramipril (sold under the brand name Altace ) is a prodrug belonging to the angiotensin-converting enzyme (ACE) inhibitors. It is metabolized to ramiprilat in the liver and, to a lesser extent, kidneys. Ramiprilat is a potent, competitive inhibitor of ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Ramipril is indicated for the treatment of hypertension, to lower blood pressure; also used to reduce the risk of myocardial infarction, stroke, or death from cardiovascular causes; in addition, this drug is used to reduce the rate of death, myocardial infarction and stroke in individuals at high risk of cardiovascular events.

CNS Activity

Originator

Approval Year

1991
122
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8504
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8583
ALTACE

Approved Use

Reduction in Risk of Myocardial Infarction, Stroke, and Death from Cardiovascular Causes Ramipril capsules are indicated in patients 55 years or older at high risk of developing a major cardiovascular event because of a history of coronary artery disease, stroke, peripheral vascular disease, or diabetes that is accompanied by at least one other cardiovascular risk factor (hypertension, elevated total cholesterol levels, low HDL levels, cigarette smoking, or documented microalbuminuria), to reduce the risk of myocardial infarction, stroke, or death from cardiovascular causes. Ramipril capsules can be used in addition to other needed treatment (such as antihypertensive, antiplatelet or lipid-lowering therapy). Hypertension Ramipril capsules are indicated for the treatment of hypertension. It may be used alone or in combination with thiazide diuretics. In using ramipril capsules, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that ramipril capsules do not have a similar risk. (See WARNINGS.) In considering use of ramipril capsules, it should be noted that in controlled trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, ACE inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients. (See WARNINGS, Angioedema.)

Launch Date

1991
Preventing
Approved
8583
ALTACE

Approved Use

Reduction in Risk of Myocardial Infarction, Stroke, and Death from Cardiovascular Causes Ramipril capsules are indicated in patients 55 years or older at high risk of developing a major cardiovascular event because of a history of coronary artery disease, stroke, peripheral vascular disease, or diabetes that is accompanied by at least one other cardiovascular risk factor (hypertension, elevated total cholesterol levels, low HDL levels, cigarette smoking, or documented microalbuminuria), to reduce the risk of myocardial infarction, stroke, or death from cardiovascular causes. Ramipril capsules can be used in addition to other needed treatment (such as antihypertensive, antiplatelet or lipid-lowering therapy). Hypertension Ramipril capsules are indicated for the treatment of hypertension. It may be used alone or in combination with thiazide diuretics. In using ramipril capsules, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that ramipril capsules do not have a similar risk. (See WARNINGS.) In considering use of ramipril capsules, it should be noted that in controlled trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, ACE inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients. (See WARNINGS, Angioedema.)

Launch Date

1991
Primary
Approved
8583
ALTACE

Approved Use

Reduction in Risk of Myocardial Infarction, Stroke, and Death from Cardiovascular Causes Ramipril capsules are indicated in patients 55 years or older at high risk of developing a major cardiovascular event because of a history of coronary artery disease, stroke, peripheral vascular disease, or diabetes that is accompanied by at least one other cardiovascular risk factor (hypertension, elevated total cholesterol levels, low HDL levels, cigarette smoking, or documented microalbuminuria), to reduce the risk of myocardial infarction, stroke, or death from cardiovascular causes. Ramipril capsules can be used in addition to other needed treatment (such as antihypertensive, antiplatelet or lipid-lowering therapy). Hypertension Ramipril capsules are indicated for the treatment of hypertension. It may be used alone or in combination with thiazide diuretics. In using ramipril capsules, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that ramipril capsules do not have a similar risk. (See WARNINGS.) In considering use of ramipril capsules, it should be noted that in controlled trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, ACE inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients. (See WARNINGS, Angioedema.)

Launch Date

1991
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
43.8 ng/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/2533075
5 mg 1 times / day steady-state, oral
dose: 5 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
RAMIPRIL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
24 ng/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/6097458
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RAMIPRILAT serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
197 ng × h/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/2533075
5 mg 1 times / day steady-state, oral
dose: 5 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
RAMIPRIL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
414 μg × h/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/6097458
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RAMIPRILAT serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
113 h
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/6097458
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RAMIPRILAT serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725026/
unhealthy, 18-75
Health Status: unhealthy
Age Group: 18-75
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725026/
Other AEs: Headache, Cough...
Other AEs:
Headache (13%)
Cough (33%)
Dizziness (13%)
Asthenia (19%)
Cramps (4%)
Diarrhea (4%)
Nausea (8%)
Palpitations (1%)
Dyspnea (1%)
Tinnitus (1%)
Malaise (3%)
Pruritus (1%)
Dry mouth (1%)
Polyuria (3%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725026/
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725024/
unhealthy, 55.7 years (range: 21-88 years)
Health Status: unhealthy
Age Group: 55.7 years (range: 21-88 years)
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725024/
Other AEs: Dizziness, Vertigo...
Other AEs:
Dizziness (6%)
Vertigo (6%)
Asthenia (4%)
Nausea (3%)
Headache (2%)
Abdominal pain (1%)
Gastrointestinal disorder (1%)
Rash (1%)
Cough increased (1%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725024/
AEs

AEs

AESignificanceDosePopulation
Dry mouth 1%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725026/
unhealthy, 18-75
Health Status: unhealthy
Age Group: 18-75
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725026/
Dyspnea 1%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725026/
unhealthy, 18-75
Health Status: unhealthy
Age Group: 18-75
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725026/
Palpitations 1%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725026/
unhealthy, 18-75
Health Status: unhealthy
Age Group: 18-75
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725026/
Pruritus 1%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725026/
unhealthy, 18-75
Health Status: unhealthy
Age Group: 18-75
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725026/
Tinnitus 1%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725026/
unhealthy, 18-75
Health Status: unhealthy
Age Group: 18-75
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725026/
Dizziness 13%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725026/
unhealthy, 18-75
Health Status: unhealthy
Age Group: 18-75
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725026/
Headache 13%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725026/
unhealthy, 18-75
Health Status: unhealthy
Age Group: 18-75
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725026/
Asthenia 19%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725026/
unhealthy, 18-75
Health Status: unhealthy
Age Group: 18-75
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725026/
Malaise 3%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725026/
unhealthy, 18-75
Health Status: unhealthy
Age Group: 18-75
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725026/
Polyuria 3%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725026/
unhealthy, 18-75
Health Status: unhealthy
Age Group: 18-75
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725026/
Cough 33%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725026/
unhealthy, 18-75
Health Status: unhealthy
Age Group: 18-75
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725026/
Cramps 4%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725026/
unhealthy, 18-75
Health Status: unhealthy
Age Group: 18-75
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725026/
Diarrhea 4%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725026/
unhealthy, 18-75
Health Status: unhealthy
Age Group: 18-75
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725026/
Nausea 8%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725026/
unhealthy, 18-75
Health Status: unhealthy
Age Group: 18-75
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725026/
Abdominal pain 1%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725024/
unhealthy, 55.7 years (range: 21-88 years)
Health Status: unhealthy
Age Group: 55.7 years (range: 21-88 years)
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725024/
Cough increased 1%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725024/
unhealthy, 55.7 years (range: 21-88 years)
Health Status: unhealthy
Age Group: 55.7 years (range: 21-88 years)
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725024/
Gastrointestinal disorder 1%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725024/
unhealthy, 55.7 years (range: 21-88 years)
Health Status: unhealthy
Age Group: 55.7 years (range: 21-88 years)
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725024/
Rash 1%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725024/
unhealthy, 55.7 years (range: 21-88 years)
Health Status: unhealthy
Age Group: 55.7 years (range: 21-88 years)
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725024/
Headache 2%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725024/
unhealthy, 55.7 years (range: 21-88 years)
Health Status: unhealthy
Age Group: 55.7 years (range: 21-88 years)
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725024/
Nausea 3%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725024/
unhealthy, 55.7 years (range: 21-88 years)
Health Status: unhealthy
Age Group: 55.7 years (range: 21-88 years)
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725024/
Asthenia 4%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725024/
unhealthy, 55.7 years (range: 21-88 years)
Health Status: unhealthy
Age Group: 55.7 years (range: 21-88 years)
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725024/
Dizziness 6%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725024/
unhealthy, 55.7 years (range: 21-88 years)
Health Status: unhealthy
Age Group: 55.7 years (range: 21-88 years)
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725024/
Vertigo 6%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725024/
unhealthy, 55.7 years (range: 21-88 years)
Health Status: unhealthy
Age Group: 55.7 years (range: 21-88 years)
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725024/
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CES1
45

CES2
33
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
PEPT1
29
 yes
PEPT2
17
 yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CES2
33
 no
CES1
45
 yes
PubMed

PubMed

TitleDatePubMed
Changes in vasoconstrictive hormones, natriuretic peptides, and left ventricular remodeling soon after anterior myocardial infarction.
2001-12
Prevention, protection, and the intrarenal renin-angiotensin systems.
2001-11
The effects of an ACE inhibitor and a calcium antagonist on the progression of renal disease: the Nephros Study.
2001-11
Simvastatin reverses impaired regulation of renal oxygen consumption in congestive heart failure.
2001-11
Blacks with hypertension, renal insufficiency, and baseline proteinuria benefit more from ACE inhibition than from calcium channel blockade.
2001-10-26
[Atherosclerosis. High ACE activity in plaque: risk of rupture!].
2001-10-25
Ramipril and the development of diabetes.
2001-10-17
Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril.
2001-10-02
Clinical trials report. The effect of Ramipril versus Amlodipine on renal outcomes in hypertension nephrosclerosis.
2001-10
[Ramipril can do more. Halting progression of atherosclerosis].
2001-09-06
[Achieving vascular protection. ACE inhibitor lowers not only blood pressure].
2001-09-06
Can ACE inhibitor therapy prevent end-stage renal failure?
2001-09-03
Inhibition of cyclooxygenase-2 attenuates urinary prostanoid excretion without affecting renal renin expression.
2001-09
What is the best treatment for slowing the progression to end-stage renal disease (ESRD) in African Americans with hypertensive nephropathy?
2001-09
What is the relevance of the HOPE study in general practice?
2001-09
Enantioseparation of the anticoagulant drug phenprocoumon in capillary electrophoresis with UV and laser-induced fluorescence detection and application of the method to urine samples.
2001-09
Apstatin, a selective inhibitor of aminopeptidase P, reduces myocardial infarct size by a kinin-dependent pathway.
2001-09
Inhibitors of bradykinin-inactivating enzymes decrease myocardial ischemia/reperfusion injury following 3 and 7 days of reperfusion.
2001-09
The Heart Outcomes Prevention Evaluation study: angiotensin-converting enzyme inhibitors: are their benefits a class effect or do individual agents differ?
2001-09
[Diabetic nephropathy. Smoking also damages the kidney].
2001-08-23
Cardioprotective effects of ramipril and losartan in right ventricular pressure overload in the rabbit: importance of kinins and influence on angiotensin II type 1 receptor signaling pathway.
2001-08-21
Prospective randomized controlled multicenter trial on steroids plus ramipril in proteinuric IgA nephropathy.
2001-08-17
Impaired angiotensin II regulation of renal C-type natriuretic peptide mRNA expression in experimental diabetes mellitus.
2001-08-15
Renal insufficiency predicts cardiovascular disease in high-risk individuals: the benefit of ramipril in the HOPE study. Heart Outcomes and Prevention Evaluation.
2001-08-11
The African American Study of Kidney Disease and Hypertension (AASK): new findings.
2001-08-11
[Effect of a non-antihypertensive dose of ramipril on the plasma and tissue renin-angiotensin system in 27 TGR (mRen2) rats].
2001-08
HOPE for patients with Type 2 diabetes: an application of the findings of the MICRO-HOPE substudy in a British hospital diabetes clinic.
2001-08
The HOPE study: comparison with other trials of secondary prevention.
2001-08
Effects of ramipril on coronary events in high-risk persons: results of the Heart Outcomes Prevention Evaluation Study.
2001-07-31
Study at up to 700 sites will build on landmark HOPE trial.
2001-07-28
Simultaneous determination of hydrochlorothiazide and several inhibitors of angiotensin-converting enzyme by capillary electrophoresis.
2001-07-27
[Therapeutic perspectives: association of ACE inhibitors and angiotensin receptor blockers].
2001-07-10
[Severe hypoglycemia secondary to angiotensin-converting-enzyme inhibitors in the absence of diabetes mellitus. Report of a case].
2001-07-04
Podocyte foot process broadening in experimental diabetic nephropathy: amelioration with renin-angiotensin blockade.
2001-07
Right atrial function in hypertensive patients: effects of antihypertensive therapy.
2001-07
Potentiation of kinin analogues by ramiprilat is exclusively related to their degradation.
2001-07
Bradykinin metabolism in the isolated perfused rabbit heart.
2001-07
[Decreased platelet aggregation during angiotensin-converting enzyme inhibitor therapy. Results of a pilot study].
2001-06-15
Differential effects of angiotensin AT1 and AT2 receptors on the expression, translation and function of the Na+-H+ exchanger and Na+-HCO3- symporter in the rat heart after myocardial infarction.
2001-06-15
ACE inhibitor inhibits atherosclerosis.
2001-05
An ACE inhibitor to coronary patients: ramipril reduces mortality according to HOPE trial.
2001-04
Use of 7-fluoro-4-nitrobenzo-2-oxo-1,3-diazole (NBD-F) for the determination of ramipril in tablets and spiked human plasma.
2001-04
Diabetes and the HOPE study: implications for macrovascular and microvascular disease.
2001-01
Future perspectives and implications.
2001-01
Pharmacoeconomic impact of HOPE.
2001-01
Modifying the natural history of atherosclerosis: the SECURE trial.
2001-01
Mechanical vs intrinsic components in the improvement of brachial arterial compliance. Comparison of the effects of atenolol versus ramipril in hypertensive patients.
2001
[Activity of the renin-angiotensin-aldosterone system and its impact on the effectiveness of treatment of chronic heart failure in patients with pulmonary tuberculosis].
2001
Cost effectiveness of ramipril in patients with non-diabetic nephropathy and hypertension: economic evaluation of Ramipril Efficacy in Nephropathy (REIN) Study for Germany from the perspective of statutory health insurance.
2001
Differential regulation of cathepsin B and prorenin gene expression in renal juxtaglomerular cells.
2001
Patents

Patents

06407262
2
20010002262
19
JP1066130A
10
JP2001501189A
7
JP2001508027A
38
JP2002535367A
25
JP2002536332A
39
JP2002538172A
23
JP2002541106A
100
JP2002541233A
406
JP2003501461A
2
JP2003503381A
36
JP2003507418A
31
JP2003508349A
46
JP2003515526A
470
JP2004531567A
7
JP2005500299A
34
JP2005527208A
2
JP2005527462A
22
JP2007514770A
77
JP2007518794A
2
JP2007520453A
36
JP2007524644A
51
JP2007525670A
150
JP2008167697A
2
JP2011506455A
52
JP2011510003A
50
JP2011510067A
60
JP2011524416A
146
JP2011528275A
456
JP2012500806A
10
JP2013544275A
6
JP4139440B2
7
JP4606172B2
29
JP4687863B2
2
JP4705912B2
48
JP4729259B2
38
JP4733348B2
2
JP4746258B2
2
JP4800961B2
2
JPH00219326A
2
JPH01165596A
2
JPH02121922A
14
JPH0219326A
2
JPH04179441A
2
JPH04308533A
5
JPS6466130A
5

Sample Use Guides

In Vivo Use Guide
Hypertension: The recommended initial dose for patients not receiving a diuretic is 2.5 mg once a day. Adjust dose according to blood pressure response. The usual maintenance dosage range is 2.5 mg to 20 mg per day administered as a single dose or in two. Myocardial Infarction, Stroke, and Death from Cardiovascular Causes: Initiate dosing at 2.5 mg once daily for 1 week, 5 mg once daily for the next 3 weeks, and then increase as tolerated, to a maintenance dose of 10 mg once daily. equally divided doses. In some patients treated once daily, the antihypertensive effect may diminish toward the end of the dosing interval. Heart Failure Post-Myocardial Infarction: the recommended starting dose is 2.5 mg twice daily (5 mg per day). A patient who becomes hypotensive at this dose may be switched to 1.25 mg twice daily. After one week at the starting dose, increase dose (if tolerated) toward a target dose of 5 mg twice daily, with dosage increases being about 3 weeks apart.
Route of Administration: Oral
In Vitro Use Guide
Curator's Comment: The effect of ramipril on DNA synthesis, cell proliferation and PDGF A and B chain gene expression in fetal calf serum (FCS)-activated cultured human glomerular mesangial cells was investigated. Ramipril significantly reduced FCS-induced PDGF A and B chain gene expression, completely abolished the PDGF A and B chain gene expression induced by phorbol 12-myristate 13-acetate, a specific protein kinase C activator, suggesting a site of action downstream of this enzyme in the mitogenic signal transduction pathway.
Unknown
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:32:04 GMT 2025
Edited
by admin
on Mon Mar 31 18:32:04 GMT 2025
Record UNII
6N5U4QFC3G
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
RAMIPRILAT
INN  
INN  
Official Name English
RAMIPRIL DIACID
Preferred Name English
RAMIPRIL IMPURITY E [EP IMPURITY]
Common Name English
ramiprilat [INN]
Common Name English
Classification Tree Code System Code
NDF-RT N0000175562
Created by admin on Mon Mar 31 18:32:04 GMT 2025 , Edited by admin on Mon Mar 31 18:32:04 GMT 2025
EU-Orphan Drug EU/3/13/1117
Created by admin on Mon Mar 31 18:32:04 GMT 2025 , Edited by admin on Mon Mar 31 18:32:04 GMT 2025
NCI_THESAURUS C247
Created by admin on Mon Mar 31 18:32:04 GMT 2025 , Edited by admin on Mon Mar 31 18:32:04 GMT 2025
Code System Code Type Description
PUBCHEM
5464096
Created by admin on Mon Mar 31 18:32:04 GMT 2025 , Edited by admin on Mon Mar 31 18:32:04 GMT 2025
PRIMARY
IUPHAR
6344
Created by admin on Mon Mar 31 18:32:04 GMT 2025 , Edited by admin on Mon Mar 31 18:32:04 GMT 2025
PRIMARY
DRUG BANK
DB14208
Created by admin on Mon Mar 31 18:32:04 GMT 2025 , Edited by admin on Mon Mar 31 18:32:04 GMT 2025
PRIMARY
INN
5713
Created by admin on Mon Mar 31 18:32:04 GMT 2025 , Edited by admin on Mon Mar 31 18:32:04 GMT 2025
PRIMARY
MESH
C052549
Created by admin on Mon Mar 31 18:32:04 GMT 2025 , Edited by admin on Mon Mar 31 18:32:04 GMT 2025
PRIMARY
DAILYMED
6N5U4QFC3G
Created by admin on Mon Mar 31 18:32:04 GMT 2025 , Edited by admin on Mon Mar 31 18:32:04 GMT 2025
PRIMARY
CAS
87269-97-4
Created by admin on Mon Mar 31 18:32:04 GMT 2025 , Edited by admin on Mon Mar 31 18:32:04 GMT 2025
PRIMARY
RXCUI
1546377
Created by admin on Mon Mar 31 18:32:04 GMT 2025 , Edited by admin on Mon Mar 31 18:32:04 GMT 2025
PRIMARY RxNorm
ChEMBL
CHEMBL1201365
Created by admin on Mon Mar 31 18:32:04 GMT 2025 , Edited by admin on Mon Mar 31 18:32:04 GMT 2025
PRIMARY
EVMPD
SUB10249MIG
Created by admin on Mon Mar 31 18:32:04 GMT 2025 , Edited by admin on Mon Mar 31 18:32:04 GMT 2025
PRIMARY
NCI_THESAURUS
C72911
Created by admin on Mon Mar 31 18:32:04 GMT 2025 , Edited by admin on Mon Mar 31 18:32:04 GMT 2025
PRIMARY
FDA UNII
6N5U4QFC3G
Created by admin on Mon Mar 31 18:32:04 GMT 2025 , Edited by admin on Mon Mar 31 18:32:04 GMT 2025
PRIMARY
CHEBI
77363
Created by admin on Mon Mar 31 18:32:04 GMT 2025 , Edited by admin on Mon Mar 31 18:32:04 GMT 2025
PRIMARY
EPA CompTox
DTXSID401016165
Created by admin on Mon Mar 31 18:32:04 GMT 2025 , Edited by admin on Mon Mar 31 18:32:04 GMT 2025
PRIMARY
SMS_ID
100000080313
Created by admin on Mon Mar 31 18:32:04 GMT 2025 , Edited by admin on Mon Mar 31 18:32:04 GMT 2025
PRIMARY
Related Record Type Details
Structure of RAMIPRIL
PRODRUG -> METABOLITE ACTIVE
Related Record Type Details
Structure of RAMIPRIL
PARENT -> IMPURITY
UNSPECIFIED
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
Structure of RAMIPRILAT
ACTIVE MOIETY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966